Skip to content

Trial Summary

The purpose of this study is to determine whether accelerated BEP chemotherapy is more effective than standard BEP chemotherapy in males with intermediate and poor-risk metastatic germ cell tumours

Acronym:

BEP3

ACTRN/NCT /ethics:

NCT02582697
Ethics: 384.14

Scientific title:

Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

Sponsor / Cooperative group:

University of Sydney

Trial & Patient Characteristics

Cancer TypeNeuroendocrine
Trial TypeTreatment
PhasePhase III
Age Range11- 45 years
SexBoth
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced, Metastatic or Widespread
Anticipated Start Date2014-02-01
Anticipated End Date2023-07-01

Participating Hospitals

HospitalFlinders Medical Centre
Clinical Trial CoordinatorAlex Scott-Hoy
Emailalex.scott-hoy@sa.gov.au
Phone08 8204 4830
Principal InvestigatorDr Ganessan Kichenadasse
Recruitment StatusRecruiting